Eli Lilly Expands Portfolio with Acquisitions of Sigilon Therapeutics and Versanis Bio
Eli Lilly (NYSE: LLY) has completed the separate purchases of US compatriots Sigilon Therapeutics (NASDAQ:...
NHC Addresses Anti-Corruption Efforts in Pharmaceutical Industry Nationwide
The National Health Commission (NHC) convened a conference to address questions on the ongoing anti-corruption...
Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma
This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...
Novartis Acquires Chinook Therapeutics for $3.2 Billion, Eyes Kidney Disease Market
Switzerland-based pharmaceutical major Novartis (NYSE: NVS) has successfully completed the scheduled purchase of US-based kidney...
Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) announced last week that it...
Novo Nordisk to Acquire Inversago Pharma in a Deal Valued Up to USD 1.1 Billion
Denmark’s leading pharmaceutical company, Novo Nordisk (NYSE: NVO), has reached an agreement to acquire Canada-based...
Telix Pharmaceuticals and Grand Pharma Initiate Phase III Trial for Illucix in China
Australian biotechnology company Telix Pharmaceuticals Ltd (ASX: TLX) and its China market partner, Grand Pharmaceutical...
Mirxes Holding Company Receives FDA Breakthrough Device Designation for GASTROClea
Singapore-based RNA technology company, Mirxes Holding Company Ltd, which specializes in blood-based miRNA test kit...
China Unveils State Council Measures to Boost Foreign Direct Investment
The State Council of China has demonstrated its commitment to encouraging greater foreign investment by...
Bio-Thera Solutions’ BAT8006 Shows Positive Phase I Results in Solid Tumor Treatment
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced positive Phase I clinical data for BAT8006...
Vcanbio Receives Orphan Drug Designation for VUM02 in Idiopathic Pulmonary Fibrosis Treatment
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has...
Asieris Pharmaceuticals’ Hexvix Meets Primary Endpoint in Phase III Bladder Cancer Study
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has revealed that a Phase III study...
Eli Lilly Completes Acquisition of Dice Therapeutics for $2.0 Billion
Pharmaceutical giant Eli Lilly (NYSE: LLY) has successfully concluded the purchase of US-based Dice Therapeutics...
Sichuan Kelun-Biotech’s SKB264 Achieves Primary Endpoint in Phase III TNBC Study
Sichuan Kelun Pharmaceutical Co., Ltd’s innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:...
Huadong Medicine’s HDM3001, a Biosimilar to Stelara, Accepted for Review by NMPA
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
Cascade Pharmaceuticals Secures RMB140 Million in Financing to Advance FXR Agonist Clinical Trials
Shanghai-based sino-foreign joint venture, Cascade Pharmaceuticals, Inc., has reportedly raised RMB140 million in a recent...
Migrasome Therapeutics Secures Over RMB100 Million in Angel+ Funding Round
Beijing-based biotech startup Migrasome Therapeutics has reported raising upwards of RMB100 million in its angel...
CanSino BiologicsLaunches Phase III Trial for DTcP Vaccine in Infants and Young Children
CanSino Biologics Inc. a leading China-based vaccines specialist (HKG: 6185), has announced the initiation of...
Hunan HSA Implements Direct BMI Fund Payments for VBP-Winning Drugs and Consumables
The Hunan Healthcare Security Administration (HSA) bureau has released a notice stating that effective from...
SAMR and Nine Ministries Tighten Regulations on Forums and Conferences in China
The State Administration for Market Regulation (SAMR) of China, in conjunction with nine other ministries,...